# Indi Molecular

> Indi Molecular is a Culver City, California biotech developing a synthetic alternative to antibodies called Protein Catalyzed Capture (PCC) agents - small, stable cyclic peptides built with click chemistry that bind protein targets with antibody-like specificity while behaving like small-molecule drugs. Spun out of Caltech chemist James Heath's lab in 2013, the company applies its platform to targeted oncology therapeutics and PET imaging agents, aiming to reach targets long considered undruggable, including KRAS G12D pancreatic cancer and ovarian cancer.

- **Founded:** 2013
- **Headquarters:** Culver City, California, United States
- **Founders:** Albert A. Luderer (Co-Founder & CEO), James R. Heath (Co-Founder & Scientific Founder (Caltech chemist)), Leroy Hood (Co-Founder (Institute for Systems Biology))
- **Team size:** ~2 (per LinkedIn); small, lean team
- **Products:** Protein Catalyzed Capture (PCC) Platform, Oncology therapeutic candidates, PET imaging / theranostic agents
- **Notable:** Commercialized an entirely new class of compounds - protein-catalyzed capture agents - out of Caltech., Raised $26M total across seed and Series A rounds from investors including Merck Ventures and Legend Capital., Secured a co-development partnership with GE Healthcare for an immunotherapy-response PET tracer (2019).

## Products & services

- **Protein Catalyzed Capture (PCC) Platform** — A proprietary synthetic protein-chemistry discovery platform that uses patented click chemistry to build low-molecular-weight cyclic peptides (under 4 kD) with antibody-like binding specificity and small-molecule pharmacology. Developed originally with Caltech.
- **Oncology therapeutic candidates** — Synthetic small-molecule targeted therapeutics in development for ovarian cancer and KRAS G12D-expressing pancreatic cancers.
- **PET imaging / theranostic agents** — PCC-based PET tracers designed to non-invasively image tumor and immune-cell targets, including a CD8-targeting tracer developed with GE Healthcare to predict immunotherapy response.

## Achievements

- Commercialized an entirely new class of compounds - protein-catalyzed capture agents - out of Caltech.
- Raised $26M total across seed and Series A rounds from investors including Merck Ventures and Legend Capital.
- Secured a co-development partnership with GE Healthcare for an immunotherapy-response PET tracer (2019).
- Advanced oncology programs against historically 'undruggable' targets including KRAS G12D.

## Latest updates

- **2019-05** — Announced collaboration with GE Healthcare to develop PET tracers targeting CD8 for immunotherapy response.
- **2017-06** — Closed $11.5M Series A led by M Ventures and Legend Capital to accelerate PCC platform development.
- **2017-06** — Featured in C&EN for scoring its first institutional funding round.

## Links

- Website: https://indimolecular.com
- LinkedIn: http://www.linkedin.com/company/indi-molecular

---

Profile page: https://yespress.io/indi-molecular
Published by YesPress — https://yespress.io
Last updated: 2026-07-20